TY - JOUR
T1 - Using a digital tool to detect early changes in everyday functioning in older adults
T2 - A pilot study of the Assessment of Smartphone Everyday Tasks (ASSET)
AU - Dubbelman, Mark A.
AU - Hall, Tia C.
AU - Levesque, Isabella M.
AU - Mimmack, Kayden J.
AU - Sikkes, Sietske A. M.
AU - Fischer, Shira H.
AU - Rentz, Dorene M.
AU - Sperling, Reisa A.
AU - Papp, Kathryn V.
AU - Amariglio, Rebecca E.
AU - Marshall, Gad A.
N1 - Funding Information: This work was supported by a grant from the NIH/NIA (R42 AG069629) and the Vettel Family and Polayes Family funds. We would also like to acknowledge the ADK Group, who was partner in the development of ASSET. M.A.D. received grant support from Alzheimer Nederland (WE.06‐2023‐02), paid to his institution. T.C.H., I.M.L., and K.J.M. report no relevant disclosures. S.A.M.S. research programs have been funded by ZonMW (#7330502051 and #73305095008) and Health∼Holland, Topsector Life Sciences & Health (LSHM19051, LSHM20084, LSHM22026‐SGF). S.A.M.S. provided consultancy services to Prothena Biosciences, Aribio, Cogstate, Biogen, Boehringer and Toyama. All funds are paid to her institution. S.H.F., D.M.R., R.A.S., K.V.P., and R.E.A. report no relevant disclosures. G.A.M. has received research salary support for serving as site principal investigator for clinical trials funded by Eisai Inc., Eli Lilly and Company, and Genentech. These relationships are not related to the content in the manuscript. Funding Information: This work was supported by a grant from the NIH/NIA (R42 AG069629) and the Vettel Family and Polayes Family funds. We would also like to acknowledge the ADK Group, who was partner in the development of ASSET. M.A.D. received grant support from Alzheimer Nederland (WE.06-2023-02), paid to his institution. T.C.H., I.M.L., and K.J.M. report no relevant disclosures. S.A.M.S. research programs have been funded by ZonMW (#7330502051 and #73305095008) and Health∼Holland, Topsector Life Sciences & Health (LSHM19051, LSHM20084, LSHM22026-SGF). S.A.M.S. provided consultancy services to Prothena Biosciences, Aribio, Cogstate, Biogen, Boehringer and Toyama. All funds are paid to her institution. S.H.F., D.M.R., R.A.S., K.V.P., and R.E.A. report no relevant disclosures. G.A.M. has received research salary support for serving as site principal investigator for clinical trials funded by Eisai Inc., Eli Lilly and Company, and Genentech. These relationships are not related to the content in the manuscript. Publisher Copyright: © 2023 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - INTRODUCTION: To investigate the utility of a new digital tool for measuring everyday functioning in preclinical Alzheimer's disease, we piloted the Assessment of Smartphone Everyday Tasks (ASSET) application. METHODS: Forty-six participants (50.3 ± 27.1 years; 67% female; 20 young unimpaired, 17 old unimpaired, 9 mildly cognitively impaired) completed ASSET 7 times. ASSET comprises two main tasks, simulating a Patient Portal and a Calendar. We assessed ASSET's internal consistency, test–retest reliability, and user experience. RESULTS: ASSET main tasks correlated with each other (r = 0.75, 95% confidence interval [CI] = [0.58, 0.86]). Performance on ASSET's Patient Portal related to cognition (r = 0.64, 95% CI = [0.42, 0.79]) and observer ratings of everyday functioning (r = 0.57, 95% CI = [0.24, 0.79]). Test–retest reliability was good (intraclass correlation coefficient = 0.87, 95% CI = [0.77, 0.93]). Most participants rated their experience with ASSET neutrally or positively. DISCUSSION: ASSET is a promising smartphone-based digital assessment of everyday functioning. Future studies may investigate its utility for early diagnosis and evaluation of treatment of Alzheimer's disease.
AB - INTRODUCTION: To investigate the utility of a new digital tool for measuring everyday functioning in preclinical Alzheimer's disease, we piloted the Assessment of Smartphone Everyday Tasks (ASSET) application. METHODS: Forty-six participants (50.3 ± 27.1 years; 67% female; 20 young unimpaired, 17 old unimpaired, 9 mildly cognitively impaired) completed ASSET 7 times. ASSET comprises two main tasks, simulating a Patient Portal and a Calendar. We assessed ASSET's internal consistency, test–retest reliability, and user experience. RESULTS: ASSET main tasks correlated with each other (r = 0.75, 95% confidence interval [CI] = [0.58, 0.86]). Performance on ASSET's Patient Portal related to cognition (r = 0.64, 95% CI = [0.42, 0.79]) and observer ratings of everyday functioning (r = 0.57, 95% CI = [0.24, 0.79]). Test–retest reliability was good (intraclass correlation coefficient = 0.87, 95% CI = [0.77, 0.93]). Most participants rated their experience with ASSET neutrally or positively. DISCUSSION: ASSET is a promising smartphone-based digital assessment of everyday functioning. Future studies may investigate its utility for early diagnosis and evaluation of treatment of Alzheimer's disease.
KW - Alzheimer's disease
KW - application
KW - digital
KW - everyday functioning
KW - instrumental activities of daily living
KW - smartphone
UR - http://www.scopus.com/inward/record.url?scp=85180254427&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/dad2.12506
DO - https://doi.org/10.1002/dad2.12506
M3 - Article
C2 - 38111596
SN - 2352-8729
VL - 15
SP - e12506
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 4
M1 - e12506
ER -